{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Clinical Progression"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Non-evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"defined by modified RECIST 1.1 for mesothelioma","groups":[{"description":"The treatment will consist of avelumab as well as a short course of Stereotactic Body Radiation Therapy","id":"OG000","title":"Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}